NCT03105986

A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults

A Phase 1, Randomized, Open-label, Crossover Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Janssen-Cilag International NV · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of multiple-dose administration of probenecid on the pharmacokinetics of JNJ-63549109 and JNJ-64167896 after a single dose of JNJ-64041575 in healthy adult participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-64041575	Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
DRUG	Probenecid	One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).

Timeline

• Start date: 2017-04-05
• Primary completion: 2017-06-16
• Completion: 2017-06-16
• First posted: 2017-04-10
• Last updated: 2018-08-13

Locations

1 site across 1 country: Germany